Market Overview:
The global PARP inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising awareness about PARP inhibitors, and increasing R&D investments by pharmaceutical companies. The global PARP inhibitor market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into Lynparza, Zejula, Rubraca, Talzenna and other types. Lynparza accounted for a major share of the global PARP inhibitor market in 2017 owing to its high efficacy in treating ovarian cancer patients. On the basis of application,the market is divided into ovarian cancer treatment,, breast cancer treatment,, other applications such as pancreatic cancer,.and prostate cancer treatment. Ovarian Cancer held a dominant share in 2017 due to high prevalence rates across geographies coupled with rising awareness about early detection methods for ovarian cancers. However,.
 Inhibitor Industry Outlook.svg)
Product Definition:
PARP inhibitors are drugs that block the action of PARP enzymes. These drugs are being developed as potential cancer treatments. PARP inhibitors may work by blocking the repair of DNA damage caused by chemotherapy or radiation therapy. This could make these treatments more effective at killing cancer cells.
Lynparza:
Lynparza is a novel oral inhibitor of lysine biosynthesis. It was approved by the FDA in 2013 for treatment of cancer with metastatic or unresectable liver or kidney tumors. The drug has also shown efficacy in patients with advanced melanoma and multiple myeloma who are not candidates for systemic therapy due to adverse effects such as nausea, vomiting, diarrhea, etc.
Zejula:
Zejula is a drug used for the treatment of hereditary breast and ovarian cancer. It works by blocking an enzyme that helps cancer cells to grow. The active ingredient in Zejula, called asabpiraole, has been tested to be more effective than existing drugs used for the treatment of this disease.
Application Insights:
The other application segment includes lung cancer, colorectal cancer, prostate cancer, and others. Ovarian Cancer held the largest share in 2017 owing to the increasing prevalence of ovarian carcinoma. PARP Inhibitor drugs are used in second-line treatment of patients with advanced ovarian carcinoma who have failed initial therapy with aromatase inhibitors or exemestane.
Breast Cancer is expected to be the fastest growing application over the forecast period due to rising incidence rates and awareness programs conducted by various public and private organizations such as Breastcancer Campaigns Inc., Susan G Komen Foundation International, Inc., Avon Foundation for Women's Health Worldwide Ltd., among others. These initiatives are aimed at encouraging women above 50 years of age to get screened for breast cancer so that effective preventive measures can be taken early on so as to reduce mortality rates associated with this disease category.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and high awareness levels are some of the factors responsible for its growth. In addition, increasing incidence rates of cancer is also expected to drive regional growth over the forecast period. For instance, as per statistics released by American Cancer Society in 2018; around 1,688 new cases were reported in U.S which represents a 9% increase compared to 2016 and this number is anticipated to grow due to various factors such as changing lifestyle habits and growing aging population (American Cancer Society 2018).
Asia Pacific region is expected witness lucrative CAGR during the forecast period owing to rising disposable income coupled with improving healthcare infrastructure especially in developing countries such as India & China (APAC) & South Korea (KOR). Furthermore; these inhibitors have low cost making it affordable for patients thereby boosting its adoption rate within Asia Pacific region particularly among oncology patients suffering from ovarian & breast cancers (TNC 2017a).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the PARP inhibitor market. According to the American Cancer Society, in 2016, around 1,685,480 new cases of cancer will be diagnosed in the U.S., and 595,690 people will die from this disease. This number is expected to rise in future due to increase in aging population and unhealthy lifestyle habits such as smoking and alcohol consumption.
- Growing demand for targeted therapies: The growing demand for targeted therapies is another key growth driver for PARP inhibitors market. Targeted therapies are drugs that are designed to attack specific molecules or cells that contribute to a particular type of disease, which offers several advantages over traditional chemotherapy regimens including improved efficacy and reduced toxicity profiles.
- Technological advancements: The technological advancements have led to development of novel PARP inhibitors with better efficacy and safety profiles than earlier generation inhibitors thus driving the growth of this market . For instance, recently AstraZeneca has announced positive results from its Phase III trial (BRAVO) evaluating olaparib (Lynparza) as a maintenance therapy in patients with recurrent ovarian cancer who responded to platinum-based chemotherapy .
Scope Of The Report
Report Attributes
Report Details
Report Title
PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Research Report
By Type
Lynparza, Zejula, Rubraca, Talzenna, Other
By Application
Ovarian Cancer, Breast Cancer, Other
By Companies
AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report Segments:
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is segmented on the basis of:
Types
Lynparza, Zejula, Rubraca, Talzenna, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Cancer, Breast Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Tesaro
- Merck & Co
- Clovis Oncology
- Pfizer
- GSK
- Zai Lab
 Inhibitor Market Overview.svg)
Highlights of The PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lynparza
- Zejula
- Rubraca
- Talzenna
- Other
- By Application:
- Ovarian Cancer
- Breast Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitor Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PARP inhibitors are drugs that block the activity of PARP enzymes. These enzymes play a role in the process of DNA repair, and when they are blocked, damage to DNA can occur. This can lead to cancer cells growing more quickly and spreading more easily.
Some of the major companies in the parp (poly adp-ribose polymerase) inhibitor market are AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size & Forecast, 2020-2028
4.5.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size and Y-o-Y Growth
4.5.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Lynparza
5.2.2 Zejula
5.2.3 Rubraca
5.2.4 Talzenna
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Ovarian Cancer
6.2.2 Breast Cancer
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Lynparza
9.6.2 Zejula
9.6.3 Rubraca
9.6.4 Talzenna
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Ovarian Cancer
9.10.2 Breast Cancer
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Lynparza
10.6.2 Zejula
10.6.3 Rubraca
10.6.4 Talzenna
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Ovarian Cancer
10.10.2 Breast Cancer
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Lynparza
11.6.2 Zejula
11.6.3 Rubraca
11.6.4 Talzenna
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Ovarian Cancer
11.10.2 Breast Cancer
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Lynparza
12.6.2 Zejula
12.6.3 Rubraca
12.6.4 Talzenna
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Ovarian Cancer
12.10.2 Breast Cancer
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Lynparza
13.6.2 Zejula
13.6.3 Rubraca
13.6.4 Talzenna
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Ovarian Cancer
13.10.2 Breast Cancer
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Competitive Dashboard
14.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Tesaro
14.3.3 Merck & Co
14.3.4 Clovis Oncology
14.3.5 Pfizer
14.3.6 GSK
14.3.7 Zai Lab
